Posted by Michael Wonder on 14 Feb 2023
Verve Therapeutics announces VERVE-101 awarded Innovation Passport by the UK MHRA for the treatment of heterozygous familial hypercholesterolaemia
14 February 2023 - Verve Therapeutics today announced that VERVE-101 has been awarded the Innovation Passport for the treatment of heterozygous familial hypercholesterolaemia under the Innovative Licensing and Access Pathway by the MHRA.
VERVE-101 is a novel, investigational gene editing medicine designed to be a single course treatment that permanently turns off the PCSK9 gene in the liver to durably lower disease driving low-density lipoprotein cholesterol.
